Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators

A new series of pyridone-core based HDAC inhibitors were synthesized for anticancer chemotherapy through RUNX3 modulation.136